|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatocellular carcinoma in viral and autoimmune liver diseases:Role of CD4+CD25+Foxp3+regulatory T cells in the immune microenvironment显示文摘More than 90%of cases of hepatocellular carcinoma(HCC)occurs in patients with cirrhosis,of which hepatitis B virus and hepatitis C virus are the leading causes,while the tumor less frequently arises in autoimmune liver diseases.Advances in understanding tumor immunity have led to a major shift in the treatment of HCC,with the emergence of immunotherapy where therapeutic agents are used to target immune cells rather than cancer cells.Regulatory T cells(Tregs)are the most abundant suppressive cells in the tumor microenvironment and their presence has been correlated with tumor progression,invasiveness,as well as metastasis.Tregs are characterized by the expression of the transcription factor Foxp3 and various mechanisms ranging from cell-to-cell contact to secretion of inhibitory molecules have been implicated in their function.Notably,Tregs amply express checkpoint molecules such as cytotoxic T lymphocyte-associated antigen 4 and programmed cell-death 1 receptor and therefore represent a direct target of immune checkpoint inhibitor(ICI)immunotherapy.Taking into consideration the critical role of Tregs in maintenance of immune homeostasis as well as avoidance of autoimmunity,it is plausible that targeting of Tregs by ICI immunotherapy results in the development of immune-related adverse events(irAEs).Since the use of ICI becomes common in oncology,with an increasing number of new ICI currently under clinical trials for cancer treatment,the occurrence of irAEs is expected to dramatically rise.Herein,we review the current literature focusing on the role of Tregs in HCC evolution taking into account their opposite etiological function in viral and autoimmune chronic liver disease,and we discuss their involvement in irAEs due to the new immunotherapies. | Alessandro Granito Luigi Muratori Claudine Lalanne Chiara Quarneti Silvia Ferri Marcello Guidi Marco Lenzi Paolo Muratori | 2021 | World Journal of Gastroenterology2021，27，22： | 11 |
| 2 | De novo autoimmune hepatitis in liver transplant: State-of-the-art review显示文摘In the two past decades, a number of communications, case-control studies, and retrospective reports have appeared in the literature with concerns about the development of a complex set of clinical, laboratory and histological characteristics of a liver graft dysfunction that is compatible with autoimmune hepatitis. The de novo prefix was added to distinguish this entity from a pre-transplant primary autoimmune hepatitis, but the globally accepted criteria for the diagnosis of autoimmune hepatitis have been adopted in the diagnostic algorithm. Indeed, de novo autoimmune hepatitis is characterized by the typical liver necroinflammation that is rich in plasma cells, the presence of interface hepatitis and the consequent laboratory findings of elevations in liver enzymes, increases in serum gamma globulin and the appearance of nonorgan specific auto-antibodies. Still, the overall features of de novo autoimmune hepatitis appear not to be attributable to a univocal patho-physiological pathway because they can develop in the patients who have undergone liver transplantation due to different etiologies. Specifically, in subjects with hepatitis C virus recurrence, an interferon-containing antiviral treatment has been indicated as a potential inception of immune system derangement. Herein, we attempt to review the currently available knowledge about de novo liver autoimmunity and its clinical management. | Ranka Vukotic Giovanni Vitale Antonia D'Errico-Grigioni Luigi Muratori Pietro Andreone | 2016 | World Journal of Gastroenterology2016，22，10： | 4 |
| 3 | Factors Associated With Response to Therapy and Outcome of Patients With Primary Biliary Cirrhosis With Features of Autoimmune Hepatitis显示文摘 | Ersan Ozaslan Cumali Efe Alexandra Heurgué–Berlot Taylan Kav Chiara Masi Tugrul Purnak Luigi Muratori Yücel Ustündag Solange Bresson–Hadni Gérard Thiéfin Thomas D. Schiano Staffan Wahlin Paolo Muratori | 2014 | Clinical Gastroenterology and Hepatology2014，，： | 3 |
| 4 | Genetic distinctions between autoimmune hepatitis in Italy and North America显示文摘AIM: Our goals were to analyze the known genetic predispositions for autoimmune hepatitis (AIH) in AIH Italian population and to compare them with North American counterparts.METHODS: Human leukocyte antigens (HLA) B8, C7, DR3,DR4, DR7, DR11, DR13, DQ2 and the B8-DR3-DQ2phenotype were determined by microlymphocytotoxicity and polymerase chain reaction in 74 Italian patients (57with type 1 and 17 with type 2 AIH) and 149 North American patients with type 1 AIH, and in adequate controls.RESULTS: B8-DR3-DQ2 occurred more frequently in Italian patients with type 1 AIH than in Italian controls (30% vs 7%, P<0.0001), but less frequently than in North American counterparts (30% vs48%, P = 0.02). DR4 occurred less frequently in Italian patients with type 1 AIH (23% vs43%,P= 0.01) and in controls (16% vs34%, P= 0.0003) than in North American counterparts. No differences were found in alleles' frequency between type 1 and type 2Italian AIH patients. DR11 had a frequency lower in type 1 Italian AIH patients than controls (17% vs35%, P= 0.01).CONCLUSION: HLA DR4 is not associated with AIH in Italy. The known HLA risk factors for ATH occur similarly in Italian patients with type 1 and type 2 AIH, and they are less frequent than in North American patients. B8-DR3-DQ2 is the predominant phenotype of type 1 AIH also in Italy, and HLA DR11 may be a regionally distinctive protective factor against type 1 AIH. | Paolo Muratori Albert J.Czaja Luigi Muratori Georgios Pappas Silvana Maccariello Fabio Cassani Alessandro Granito Rodolfo Ferrari Vilma Mantovani Marco Lenzi Francesco B.Bianchi | 2005 | World Journal of Gastroenterology2005，11，12： | 2 |
| 5 | Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis显示文摘 | Paolo Muratori Luigi Muratori Rodolfo Ferrari Fabio Cassani Giampaolo Bianchi Marco Lenzi Luis Rodrigo Antonio Linares Dolores Fuentes Francesco B Bianchi | 2003 | The American Journal of Gastroenterology2003，，2： | 2 |
| 6 | Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases显示文摘 | Cumali Efe Staffan Wahlin Ersan Ozaslan Alexandra Heurgue Berlot Tugrul Purnak Luigi Muratori Chiara Quarneti Osman Yüksel Gérard Thiéfin Paolo Muratori | 2012 | European Journal of Gastroenterology & Hepatology2012，，5： | 2 |
| 7 | New autoantibodies and autoantigens in autoimmune hepatitis显示文摘 | Francesco B Bianchi Paolo Muratori Luigi Muratori | 2002 | Clinics in Liver Disease2002，，3： | 1 |
| 8 | The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies显示文摘 | Luigi Muratori Maria Serena Longhi | 2013 | Journal of Autoimmunity2013，，： | 1 |
| 9 | Autoimmune hepatitis in Italy: The Bologna experience显示文摘 | Paolo Muratori Alessandro Granito Chiara Quarneti Silvia Ferri Rita Menichella Fabio Cassani Georgios Pappas Francesco B. Bianchi Marco Lenzi Luigi Muratori | 2009 | Journal of Hepatology2009，，6： | 1 |
| 10 | Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases显示文摘 | Cumali Efe Staffan Wahlin Ersan Ozaslan Alexandra Heurgue Berlot Tugrul Purnak Luigi Muratori Chiara Quarneti Osman Yüksel Gérard Thiéfin Paolo Muratori | 2012 | European Journal of Gastroenterology & Hepatology2012，，5： | 1 |
| 11 | Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis显示文摘 | Paolo Muratori Luigi Muratori Rodolfo Ferrari Fabio Cassani Giampaolo Bianchi Marco Lenzi Luis Rodrigo Antonio Linares Dolores Fuentes Francesco B Bianchi | 2003 | The American Journal of Gastroenterology2003，，2： | 1 |
| 12 | Autoimmune liver disease and concomitant extrahepatic autoimmune disease显示文摘 | Paolo Muratori Angela Fabbri Claudine Lalanne Marco Lenzi Luigi Muratori | 2015 | European Journal of Gastroenterology & Hepatology2015，，： | 1 |
| 13 | Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence显示文摘Hepatocellular carcinoma(HCC)is rarely associated with autoimmune paraneoplastic syndromes.We report a case of anti-transcriptional intermediary factor-1 gamma(TIF1-γ)-positive dermatomyositis(DM)as clinical presentation of HCC recurrence in a 72-year-old male patient admitted to our hospital due to fatigue,myalgia,and typical skin rash.His medical history was notable for hepatitis C-related cirrhosis,successful treatment with direct-acting antiviral agents,and previously efficacious treatment of HCC.Laboratory testing showed significant rhabdomyolysis with antiTIF1-γantibodies at high titer,and DM was diagnosed.After a careful diagnostic workup,HCC recurrence was diagnosed.After first-line corticosteroid treatment,azathioprine and intravenous immunoglobulin treatments were administered;unfortunately,he mounted only partial response.Owing to the compromised performance status,no HCC treatment was feasible,and,according to international guidelines,he received only best supportive care.Here,we discuss the diagnostic,prognostic,and pathogenic roles of anti-TIF1-γantibodies associated with paraneoplastic DM and the scant literature data on its occurrence in HCC patients.Considering the TIF1 gene family’s established role in oncogenesis,we also review the role of TIF1-γas a tumor-related neoantigen,leading to the development of clinically overt antiTIF1-γantibodies-positive DM. | Marco Ferronato Claudine Lalanne Chiara Quarneti Michele Cevolani Chiara Ricci Alessandro Granito Luigi Muratori Marco Lenzi | 2023 | Journal of Clinical and Translational Hepatology2023，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员